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investigatorsAbstract
Background: Hypertension is a common comorbidity in patients with heart failure and may contribute to
development and course of disease, but the importance of a history of hypertension in patients with prevalent
heart failure remains uncertain.
Methods: 3078 consecutively hospitalized heart failure patients (NYHA classes II-IV) were screened for the
EchoCardiography and Heart Outcome Study (ECHOS). The left ventricular ejection fraction (LVEF) was estimated by
2 dimensional transthoracic echocardiography in all patients and a subgroup of 878 patients had additional data on
pulsed wave Doppler assessment of transmitral flow available. A restrictive filling (RF) was defined as a mitral inflow
deceleration time ≤140 ms. Patients were followed for a median of 6.8 (Inter Quartile Range 6.6-7.0) years and
multivariable Cox regression models were used to assess the risk of all-cause mortality associated with hypertension.
Results: The study population had a mean age of 73 ± 11 years. 39% were female, 27% had a history of
hypertension and 48% had a RF. Over the study period, 64% of the population died. Hypertension was not
associated with increased risk of mortality, hazard ratio (HR) 0.95 (0.85-1.05). LVEF did not modify this relationship
(p for interaction = 0.7), but RF pattern substantially influenced the outcomes associated with hypertension (p for
interaction< 0.001); HR 0.75 (0.57-0.99) and 1.41 (1.08-1.84) in patients without and with RF, respectively.
Conclusions: In patients with symptomatic heart failure, a history of hypertension is associated with a substantially
increased relative risk of mortality among patients with a restrictive transmitral filling pattern.Background
Hypertension is a common comorbidity in patients with
heart failure and may contribute to development and
course of disease, but the importance of a history of
hypertension in patients with prevalent heart failure
remains uncertain. Several studies have found a history
of hypertension to be without any prognostic importance
[1-3] or even to be associated with a decreased risk of
mortality [4]. In order to better understand this relationship,* Correspondence: ca@heart.dk
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reproduction in any medium, provided the orwe investigated the outcomes associated with a history of
hypertension in an unselected cohort of patients hospita-
lized with symptomatic heart failure with emphasis on the
prognosis as dependent on left ventricle systolic and dia-
stolic function.
Methods
The EchoCardiography and Heart Outcome Study
(ECHOS) was a multicenter double-blind clinical trial
performed in Denmark, Norway and Sweden with the
purpose of comparing placebo to nolomirole 5 mg (a
pre-synaptic stimulator of DA2-dopaminergic and alpha
2-adrenergic receptors in peripheral sympathetic nerve
endings) in patients with heart failure [5]. Nolomiroletral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.





N= 3078 N= 817
(27%)
N=2255 (73%)
Age (years) 75 (53;89) 75 (54;89) 75 (53;89)
Male gender* 61% 57% 62%





58 (25;97) 57 (23;99) 58 (27;96)
Wall motion index * 1.3 (0.5;2.0) 1.5 (0.5;2.0) 1.3 (0.5;2.0)
LVEF ≤45% * 60% 55% 62%
Smokers 29% 29% 30%
Diabetes mellitus * 15% 21% 13%




Previous stroke or TIA * 11% 15% 10%
Atrial fibrillation 35% 35% 35%
COPD 24% 23% 24%
Medications at
discharge:
Betablockers * 43% 51% 41%







Diuretics 93% 92% 93%
Statins 18% 20% 18%
Nitrates 20% 19% 20%
Glycosides (digoxin)* 38% 34% 39%
Oral anticoagulants* 30% 27% 32%
Footnote: Continuous variables are presented as median 5th; 95th percentiles.*
indicates p for difference between the two sub-groups <0.05.
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present analyses, we included all patients screened for
entrance in ECHOS [5]. To be eligible for screening,
patients were required to receive treatment with diure-
tics, to be in New York Heart Association (NYHA) class
II-IV and to have had symptoms corresponding to
NYHA classes III-IV during the preceding month.
Patients with acute pulmonary edema, uncorrected
hemodynamically significant obstructive valve disease,
clinically significant obstructive cardiomyopathy, or
acute myocardial infarction (AMI) or cardiac revascular-
ization within the preceding month were excluded.
During the screening process, a full clinical examin-
ation and a transthoracic echocardiography were
obtained for all patients. The echocardiography investi-
gation did as a minimum include two dimensional
records from the parasternal (long and short axis) and
apical views (two chamber, four chamber and apical
long-axis) in order to evaluate the systolic function. In
addition, investigators were encouraged to obtain
measurements of mitral inflow (by pulsed wave Doppler
in the apical four-chamber view). All echocardiogram
records were sent to a core laboratory for evaluation.
The systolic function was estimated through the use of
wall motion index (WMI) and the left ventricular
ejection fraction (LVEF) was subsequently calculated using
a 16 segment reverse scoring system, as previously
described [6]. Measurements of transmitral filling pattern
(i.e., peak flow velocity and deceleration time in early dia-
stole [E wave] and peak flow velocity in atrial contraction
[A wave]) were obtained as averages of 5 consecutive
cardiac cycles for patients in sinus rhythm and 10 cardiac
cycles for patients in atrial fibrillation. A restrictive left
ventricular filling pattern was considered present if trans-
mitral deceleration time was below or equal to 140 ms [7].
Atrial fibrillation was no exclusion criteria, because a short
deceleration time has shown to be of similar prognostic
importance in patients with and without atrial fibrillation
[8-10]. A history of hypertension was defined by medical
history and required current or previous antihypertensive
treatment. Patients were considered to have hyperlipid-
aemia if they were medically treated or had a total
cholesterol> 5 mmol/l or LDL> 3 mmol/l. Creatinine
clearance was estimated using the Modification of Diet in
Renal Disease (MDRD) study equation [11].
Patients were screened in the period of 2001–2002 and
vital status (all-cause mortality) was obtained from the
Danish National Person Registry in November 2008.
Ethics
The study was performed in conformity with the Declar-
ation of Helsinki III and was approved by the Danish
central ethical committee. All patients gave their written,
informed consent before participating.Statistics
Continuous variables were compared with Kruskal-
Wallis test and discrete variables with chi-square test.
Mortality curves were generated using the Kaplan-Meier
estimators and test of equality over strata was performed
using the log-rank test. Cox proportional hazard models
were used for analyses of the relative risk of all-cause
mortality. All models included the following covariates:
gender, age, smoking, and a history of the following con-
ditions: hyperlipideamia, ischemic heart disease, stroke,
diabetes, chronic obstructive pulmonary disease, and
atrial fibrillation. The prognostic importance of a history
of hypertension as dependent on LVEF, a restrictive fill-
ing pattern and left ventricle posterior wall diameter, re-
spectively, was tested by inclusion of variables plus an
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analyzed in stratified subgroups.
Results
In total 3078 patients were screened. Of these 878
patients had complete measurements of the mitral
inflow, LVEF and hypertension status. (880 patients had
measurements of mitral inflow, but two of these lacked
data on hypertension status). Baseline characteristics for
overall population and for patients with and without
hypertension are shown in Table 1, and for patients with
and without hypertension stratified by mitral filling pat-
tern in Table 2. Overall, the mean age was 75 (±standard
deviation 11) years, 39% were female and 27% had hyper-
tension. Of the subgroup with data on deceleration time,
135 patients with hypertension and 318 patients without
hypertension had a non-restrictive filling pattern,
whereas 122 and 303 patients with and withoutTable 2 Baseline characteristics of patients with measuremen
Hypertension (n
Restrictive (n = 122) Non-
Age (years) 74 (52;87)
Male gender 60%




E/A ratio * 1.8 (0.6;3.4)
Creatinine clearance (mL/min/1.73 m2) 58 (18;97)
Wall motion index * 1.3 (0.5;2.0)
LVEF ≤45% * 64%
Left ventricle posterior wall thickness (mm) * 12 (9;17)
Smokers 33%
Diabetes mellitus * 19%
Hyperlipidaemia 37%
History of ischemic heart disease 44%






Angiotensin II blockers * 12%






Footnote: Continuous variables are presented as median 5th; 95th percentiles.* indichypertension had a restrictive filling pattern. The four
groups resembled each other in most variables, although
there were small differences in the prevalence of diabetes
mellitus, LVEF and pharmacological treatment between
the groups.
Survival analyses
Over a median follow-up time of 6.8 (Inter Quartile
Range 6.6-7.0) years, 67% of the population died.
Unadjusted mortality rates for patients with and without
hypertension are shown in Figure 1. In overall multivari-
able Cox analysis, hypertension was associated with a
hazard ratio (HR) of 0.95 (95% Confidence Interval [CI]
0.85-1.05) and was not found to be modified by LVEF (p
for interaction between LVEF and hypertension = 0.7). In
separate analyses of patients with and without a restrict-
ive filling pattern, the LVEF was without importance for
the prognosis associated with hypertension in bothts of mitral inflow available
= 257) No hypertension (n = 621)
restrictive (n = 135) Restrictive (n = 303) Non-restrictive (n = 318)
75 (55;90) 74 (52;90) 76 (53;90)
55% 61% 61%
26.5 (19.5;36.0) 25.3 (18.4;35.3) 25.0 (18.4;36.7)
187 (145;278) 116 (84;137) 171 (143;296)
1.0 (0.6;2.6) 1.5 (0.6;3.1) 1.0 (0.6;3.1)
57 (21;99) 63 (29;100) 57 (26;96)
1.6 (0.6;2.0) 1.1 (0.5;2.0) 1.4 (0.6;2.0)
48% 75% 58%

















ates p for difference between the four sub-groups <0.05.
Figure 1 Unadjusted mortality rates for patients with and
without hypertension (HT).
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with and without restrictive filling pattern, respectively).
Figure 2 a + b presents Kaplan-Meier curves for
patients with and without a restrictive filling pattern
stratified by hypertension status. As previously shown
[7], having a restrictive filling pattern was associated with
an increased risk of mortality, but importantly this rela-
tive risk was substantially higher among patients with
hypertension than among patients without hypertension
(Figure 3a). Further, the transmitral filling pattern was
shown to substantially influence the outcomes associated
with hypertension; p for interaction <0.001; Figure 3b. A
history of hypertension was associated with 25% decreaseFigure 2 a: Unadjusted mortality rates in patients with hypertension,
patients without hypertension, stratified by a restrictive filling (RF).in relative risk of mortality (HR 0.75 [0.57-0.99]) among
those with a non-restrictive filling pattern and a 41% in-
crease in relative risk of mortality (HR 1.41 [1.08-1.84])
among those with a restrictive filling pattern. As
Figure 3b also illustrates, the hazard ratios associated with
hypertension in relation to the mitral filling pattern were
not dependent on LVEF. In subgroup analysis of patients
with available measurements on left ventricle posterior
wall diameter (n= 753), no interaction was found between
hypertension and left ventricle posterior wall (p = 0.4).Discussion
The present study demonstrated that the prognostic im-
portance of a history of hypertension in unselected heart
failure patients is dependent on the diastolic, but not the
systolic, function. We found that in patients with a
restrictive filling pattern (i.e., a mitral deceleration time
<140 ms), a history of hypertension was associated a
substantial increase in relative risk of mortality (HR=
1.41 [1.08-1.84]). This relationship was established
across the whole LVEF spectrum and LVEF did not
modify the prognosis associated with a history of hyper-
tension. For comparison, such an increase is of similar
magnitude as e.g. the risk carried by diabetes [12]. Thus,
the presence of hypertension in patients with heart
failure and restrictive transmitral filling pattern, irrespec-
tively of LVEF, merits increased attention and these
patients may be candidates for more aggressive anti-
hypertensive pharmacotherapy in order to improve
prognosis. However, the benefit of anti-hypertensive
treatment in this group of patients remains to be estab-
lished and e.g. the Perindopril in Elderly People with
Chronic Heart Failure (PEP-CHF) study, which compared
perindopril to placebo in patients with preserved LVEFstratified by a restrictive filling (RF). b: Unadjusted mortality rates in
Figure 3 a: Hazard ratios associated with a restrictive filling pattern (RF) overall and in patients with and without a history of
hypertension (HT). b: Hazard ratios associated with hypertension (HT) in different subgroups of patients. RF = restrictive filling pattern; LVEF = left
ventricular ejection fraction.
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proximately 200 ms), found no effect on mortality [13].
An important limitation of the present study was that
we had no data on actual blood pressure values and it is
possible that patients included in our study were ad-
equately regulated in blood pressure. Thus, the mechan-
isms underlying our findings of an adverse prognosis
associated with a history of hypertension only in patients
with restrictive filling may also have related to other
factors than poor anti-hypertensive treatment. In this
context, hypertension may lead to left ventricular hyper-
trophy and remodeling in some patients, but not in
others, and a differential response to anti-hypertensive
treatment on left ventricle remodeling has been demon-
strated in one previous study [14]. In this latter study,
those hypertensive patients who responded to anti-
hypertensive pharmacological treatment with a reduction
in left ventricular mass were shown to have a more
favorable prognosis than patients who did not respond
with a reduction in left ventricular mass [14].
Another possible mechanism explaining our findings
may relate to severe systemic hypertension leading to
pulmonary hypertension through increased end-diastolic
pressure, and the presence of pulmonary hypertension in
patients with heart failure has shown to be a strong and
independent adverse prognosticator [15]. In this context,
it is well-known that high right ventricular pressure may
interact with left ventricular pressure, leading to a short
deceleration time [16]. Further supporting this theory, a
short deceleration time has shown to have a close correl-
ation with pulmonary capillary wedge pressure in
patients with left ventricular systolic dysfunction [17].
Finally worth discussing, in the subgroup of patients
without a restrictive filling, we found a paradoxical low
relative risk of mortality associated with a history of
hypertension (HR= 0.75 [0.57-0.99]). It is indeed well-known that high blood pressure at time of heart failure
admission is associated with a paradoxical protective ef-
fect on the risk of mortality [18-21]. Possibly, such a
paradoxical effect may be driven by more severe cardiac
dysfunction leading to a decline in systemic blood pres-
sure, thereby making low blood pressure a marker of
more advanced heart failure. A similar protective effect
on mortality risk in heart failure cohorts is known for
other classical risk factors for cardiovascular morbidity
and mortality, e.g. obesity and hypercholesterolaemia
and the reasons have been intensively discussed [18].
Limitations
Some important limitations should be noted. As previ-
ously mentioned, data on exact blood pressure values
were not available for the present study and the diagno-
sis of hypertension relied on patient history and anti-
hypertensive treatment. LVEF was estimated by WMI,
which to some extent is observer-dependent and only an
approximation of LVEF. It cannot be excluded that the
lack of interaction between left ventricle posterior wall
diameter and a history of hypertension may be due to in-
sufficient power, because measurements of left ventricle
posterior wall diameter were available in approximately
one third of all patients. Furthermore, measurements of
transmitral flow were not mandatory for the ECHOS
trial and only a subgroup of 880 patients had measure-
ments available. These patients resembled the other
patients, but it cannot fully be excluded that this
subgroup differed in unmeasured characteristics from
the rest of the ECHOS screening population. Unfortu-
nately, we did not have measurements from tissue Dop-
pler or other modern echocardiographic modalities
available for analyses (they do however not as yet allow
analyses of long-term outcomes). Finally, we did not have
causes of deaths available for the present analyses, but
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with heart failure (NYHA II-IV) die from pump failure
or arrhythmias [22].
Conclusion and clinical implication
In patients with symptomatic heart failure, a history of
hypertension is associated with a substantially increased
relative risk of mortality among patients with a restrictive
transmitral filling pattern. An increased awareness of this
poor prognosis is warranted and these patients may be
candidates to more aggressive anti-hypertensive pharma-
cotherapy in order to improve prognosis. However, the
effect of anti-hypertensive treatment in this patient-
group is as yet not well-investigated.
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